◀ Back to PRKCA
HRAS — PRKCA
Pathways - manually collected, often from reviews:
-
KEGG MAPK signaling pathway:
PRKCA/PRKCB/PRKCG
→
HRAS/KRAS/MRAS/NRAS/RRAS/RRAS2
(protein-protein, phosphorylation)
-
KEGG Pathways in cancer:
PRKCA/PRKCB/PRKCG
→
HRAS/KRAS/NRAS
(protein-protein, indirect effect)
-
KEGG Glioma:
PRKCA/PRKCB/PRKCG
→
HRAS/KRAS/NRAS
(protein-protein, activation)
-
KEGG Glioma:
PRKCA/PRKCB/PRKCG
→
HRAS/KRAS/NRAS
(protein-protein, activation)
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
PKC alpha (PRKCA)
→
RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS)
(modification, activates)
Dreikhausen et al., Int Immunol 2003, Troppmair et al., Oncogene 1992*
Evidence: mutant phenotype, other species
-
NCI Pathway Database Ras signaling in the CD4+ TCR pathway:
PKC alpha (PRKCA)
→
RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS)
(modification, activates)
Dreikhausen et al., Int Immunol 2003, Troppmair et al., Oncogene 1992*
Evidence: mutant phenotype, other species
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
PKC alpha (PRKCA)
→
RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS)
(modification, activates)
Dreikhausen et al., Int Immunol 2003, Troppmair et al., Oncogene 1992*
Evidence: mutant phenotype, other species
-
NCI Pathway Database Ras signaling in the CD4+ TCR pathway:
PKC alpha (PRKCA)
→
RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS)
(modification, activates)
Dreikhausen et al., Int Immunol 2003, Troppmair et al., Oncogene 1992*
Evidence: mutant phenotype, other species
-
NCI Pathway Database Endothelins:
HRAS/GDP complex (HRAS)
→
Typical PKCs (PRKCD/PRKCG/PRKCB/PRKCQ/PRKCB/PRKCA/PRKCE/PRKCH)
(modification, collaborate)
Arai et al., Mol Pharmacol 2003, Yogi et al., Arterioscler Thromb Vasc Biol 2007
Evidence: mutant phenotype
Text-mined interactions from Literome
Deli et al., Arch Biochem Biophys 2000
:
These results suggest that activation of the PtdEtn hydrolyzing PLD enzyme by
PKC-alpha is
inhibited by
p21 Ras
Beaudry et al., Endocrinology 2006
:
Inhibition of
PKC alpha leads to a decrease in both
p21(ras) activity and cell proliferation, which may facilitate AT2 receptor signaling through p42/p44(mapk), thereby leading to neurite outgrowth
Uberall et al., Cell Signal 1994
:
Depletion of
PKC alpha by bryostatin 1 does not
reduce the transcriptional activation of the SRE-FAP-TK-CAT ( TK : thymidine kinase ) construct by
Ha-ras
Uberall et al., Adv Enzyme Regul 1994
:
Depletion of
PKC alpha by bryostatin 1 does not
reduce the transcriptional activation of the SRE-FAP-TK-CAT-construct by
Ha-ras